Werewolf and Ambros Merge in All-Stock Deal to Fund Phase III Neridronate Trial
Werewolf Therapeutics and privately-held Ambros Therapeutics are combining in an all-stock, reverse-merger-style transaction, with Ambros valued pre-money at $500 million against Werewolf’s $47.5 million. A concurrent $150 million private placement, led by RA Capital…
